Inventage Lab has delivered the final formulation for the ‘second substance’ under its collaboration with multinational pharmaceutical company Boehringer Ingelheim, accelerating the validation of its long-acting injectable platform technology.
On April 29, Inventage Lab announced that it had handed over the final formulation for the second substance received from Boehringer in early April. Boehringer is currently conducting internal and external evaluations of the formulation and completed an on-site inspection of Inventage Lab’s platform and new manufacturing facilities in April.
“The formulation development period, which took about 10 months for the first substance, was shortened to approximately 4 months, demonstrating the excellence of our platform technology,” Inventage Lab said. “During the on-site inspection, we received feedback that they were ‘very satisfied’ with the production readiness.”
A pipeline jointly developed with Yuhan Corporation is also preparing for clinical entry. Inventage Lab aims to initiate clinical trials for ‘IVL3021’ within the year, using new equipment installed at the Quratis plant for trial production. The company expects ‘IVL3024’ to follow IVL3021 into clinical trials quickly.
Discussions are expanding around the second-generation subcutaneous injection (SC) conversion platform ‘IVL-BioFluidic’. Inventage Lab noted, “We are receiving numerous inquiries and collaboration proposals from domestic and international parties, and partnership negotiations are progressing rapidly.”
The company is currently discussing specific collaboration measures, including material transfer agreements (MTAs) and feasibility tests for IVL-BioFluidic, with multiple companies, including several global firms, in the biosimilar and antibody new drug fields.
“BioFluidic is easier to standardize as a platform compared to long-acting injectables (LAIs) and requires a shorter validation period,” Inventage Lab explained. “Since many commercialized substances do not require long-acting formulations, we expect commercialization to proceed quickly.”
In the animal health business, additional cash flow potential has emerged. Based on a pipeline previously technology-exported to Global Company A, Inventage Lab is discussing platform technology transfer, including production orders (CMO) for the product. The contract for building manufacturing facilities for this pipeline is expected to be worth hundreds of billions of Korean won, with details likely finalized in the second half of the year.
If the contract is concluded, Inventage Lab could secure both sales royalties and stable revenue from production shipments. “If this contract proceeds, it will greatly help strengthen our cash flow,” the company said.
Inventage Lab also emphasized its financial stability. “Through funding in mid-March, we secured 98.5 billion Korean won in cash,” the company stated. “Considering the potential additional cash inflow from the animal health contract, we estimate that we will face no financial difficulties for at least four years.”
Source: Read the original report | Published: May 29, 2026